In re Application of:
    Wong et al.
Application No.: Unassigned
Filed: September 4, 2003
Page 3

PATENT
Attorney Docket No.: JHU1690-3

## B. In the Claims

Please cancel claims 1 to 12, 16 to 18 and 24 to 69 without prejudice.

Following is the status of the claims:

Claims 1-12 (canceled)

13.    (original) A method for diagnosing a subject having or at risk of having an $A\beta 11$-40/42 peptide accumulation disease, the method comprising:

measuring the amount of beta-site APP-cleaving enzyme 1 (BACE1) in a biological sample from the subject;

comparing the amount BACE1 with a normal standard value of BACE1, wherein a difference between the measured amount and the normal sample or standard value provides an indication of the diagnosis of $A\beta 11$-40/42.

14.    (original) The method of claim 13, wherein the biological sample is blood, serum, cerebrospinal fluid or central nervous system (CNS) tissue.

15.    (original) The method of claim 13, wherein the difference is an increase in BACE1.

Claims 16-18 (cancelled)

19.    (original) The method of claim 13, wherein the amount of BACE1 is detected by contacting the sample with an agent that specifically binds to a BACE1 polypeptide.

In re Application of:                                          PATENT
    Wong et al.                              Attorney Docket No.:  JHU1690-3
Application No.:  Unassigned
Filed:  September 4, 2003
Page 4

20.     (original)  The method of claim 19, wherein the agent is an antibody.


21.     (original)  The method of claim 20, wherein the antibody is a monoclonal
antibody.


22.     (original)  The method of claim 20, wherein the antibody is a polyclonal antibody.


23.     (original)  The method of claim 19, wherein the $A\beta11$-40/42 accumulation disease
is Alzheimer's Disease.


Claims 24-69 (cancelled)